BR112022009199A2 - Tratamento e prevenção da dengue - Google Patents

Tratamento e prevenção da dengue

Info

Publication number
BR112022009199A2
BR112022009199A2 BR112022009199A BR112022009199A BR112022009199A2 BR 112022009199 A2 BR112022009199 A2 BR 112022009199A2 BR 112022009199 A BR112022009199 A BR 112022009199A BR 112022009199 A BR112022009199 A BR 112022009199A BR 112022009199 A2 BR112022009199 A2 BR 112022009199A2
Authority
BR
Brazil
Prior art keywords
dengue
prevention
treatment
infected
individual
Prior art date
Application number
BR112022009199A
Other languages
English (en)
Inventor
Gabriella M Goethals Olivia
Rudolf Romanie Kesteleyn Bart
Henri Theresia Stoops Bart
Bonfanti Jean-François
Hugo Maria Jonckers Tim
Van Loock Marnix
Kaptein Suzanne
Neyts Johan
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of BR112022009199A2 publication Critical patent/BR112022009199A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO E PREVENÇÃO DA DENGUE. A presente invenção refere-se ao uso de derivados de indol substituídos e derivados de indolina substituídos na fabricação de um medicamento para o tratamento de doença da dengue em um indivíduo infectado pelo vírus da dengue, ou para a prevenção da doença da dengue em um indivíduo sob risco de ser infectado pelo vírus da dengue. A invenção fornece ainda um método para o tratamento ou a prevenção da dengue em um indivíduo sob risco de estar infectado pelo vírus da dengue.
BR112022009199A 2019-11-15 2020-11-13 Tratamento e prevenção da dengue BR112022009199A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19209593 2019-11-15
EP19213851 2019-12-05
EP20171172 2020-04-23
PCT/EP2020/082102 WO2021094563A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of dengue disease

Publications (1)

Publication Number Publication Date
BR112022009199A2 true BR112022009199A2 (pt) 2022-07-26

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009199A BR112022009199A2 (pt) 2019-11-15 2020-11-13 Tratamento e prevenção da dengue

Country Status (12)

Country Link
US (1) US20220409583A1 (pt)
EP (1) EP4058019A1 (pt)
JP (1) JP2023502053A (pt)
KR (1) KR20220101679A (pt)
CN (1) CN114980884A (pt)
AU (1) AU2020382911A1 (pt)
BR (1) BR112022009199A2 (pt)
CA (1) CA3161338A1 (pt)
IL (1) IL292970A (pt)
MX (1) MX2022005879A (pt)
TW (1) TW202132269A (pt)
WO (1) WO2021094563A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218285A1 (en) * 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Also Published As

Publication number Publication date
US20220409583A1 (en) 2022-12-29
JP2023502053A (ja) 2023-01-20
MX2022005879A (es) 2022-06-14
TW202132269A (zh) 2021-09-01
KR20220101679A (ko) 2022-07-19
EP4058019A1 (en) 2022-09-21
WO2021094563A1 (en) 2021-05-20
AU2020382911A1 (en) 2022-06-30
CN114980884A (zh) 2022-08-30
CA3161338A1 (en) 2021-05-20
IL292970A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112018068956A2 (pt) derivados do composto indol substituídos como inibidores da replicação viral da dengue
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
EA201892214A1 (ru) Замещенные производные индола в качестве ингибиторов репликации вирусов денге
BR112017006708A2 (pt) indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
EA201890722A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112022009199A2 (pt) Tratamento e prevenção da dengue
EA201892389A1 (ru) Офтальмологическая композиция, содержащая синергическую комбинацию гликогена и гиалуроновой кислоты или ее соли
EA201992295A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге